Jason Halladay

San Francisco Public Library — United States

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

24h-index2.3kcitations79works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(22), Colorectal Cancer Treatments and Studies(13), Drug Transport and Resistance Mechanisms(12), Cancer therapeutics and mechanisms(12), Computational Drug Discovery Methods(11)

Publications79 total

Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
Cancer Research·2024· 2 cited
Abstract C085: OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription, including MYC, in mCRPC
Molecular Cancer Therapeutics·2023
GTP1 metabolic stability assessment: A study of the tau PET tracer [18F]GTP1
Nuclear Medicine and Biology·2023· 1 cited
The past decade of Genentech experience in elucidation of novel reaction mechanisms in drug metabolism
Medicinal Chemistry Research·2023· 4 cited
Supplemental Figure 4 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 8 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Data from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 4 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 8 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 1 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 6 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 2 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 3 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 5 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 7 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 3 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Data from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 2 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 7 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
Supplemental Figure 5 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
2023Open Access
page 1 of 4Next →

Frequent Co-authors

S. Cyrus Khojasteh(17), Susan Wong(16), Cornelis E. C. A. Hop(12), Jane R. Kenny(8), Jasleen K. Sodhi(8), Laurent Salphati(6), Young G. Shin(6), James P. Driscoll(6), Hank La(5), Emile G. Plise(5), Erlie Delarosa(5), Kirk Robarge(4), Stephen E. Gould(4), Cyrus Khojasteh(4), James C. Marsters(4), Lesley Murray(4), Lewis Gazzard(4), Harvey Wong(4), Joseph P. Lyssikatos(4), David S. Carter(4)